A discussion regarding the primary intrinsic and acquired resistance mechanisms observed in Achromobacter species. The topic aims to explore how these mechanisms contribute to the bacteria's role as emerging pathogens in clinical settings, specifically focusing on the implications for patients with cystic fibrosis.